[{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Botulinum Toxin A","moa":"\nSNAP25","graph1":"Dermatology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Botulinum Toxin A","moa":"\nSNAP25","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"FRANCE","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum Toxin A","moa":"\nSNAP25","graph1":"Urology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Galderma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Protein","year":"2023","type":"Termination","leadProduct":"Botulinum Toxin A","moa":"\nSNAP25","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Ipsen","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Galderma","highestDevelopmentStatusID":"7","companyTruncated":"Ipsen \/ Galderma"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Botulinum Toxin A","moa":"\nSNAP25","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Botulinum Toxin A","moa":"\nSNAP25","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Allergan Aesthetics","highestDevelopmentStatusID":"11","companyTruncated":"Ipsen \/ Allergan Aesthetics"},{"orgOrder":0,"company":"Ipsen","sponsor":"Galderma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"\nSNAP25||ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"ACh receptor||Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Neurology","graph2":"Phase IV","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"11","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"ACh receptor||Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"11","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"FRANCE","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Neurology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Neurology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Neurology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Neurology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Neurology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Neurology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Neurology","graph2":"Phase IV","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Neurology","graph2":"Phase IV","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Neurology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"FRANCE","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Urology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"FRANCE","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Urology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"FRANCE","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Urology","graph2":"Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"FRANCE","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Podiatry","graph2":"Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Neurology","graph2":"Phase IV","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"FRANCE","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Neurology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Neurology","graph2":"Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Neurology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Neurology","graph2":"Undisclosed","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"1","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"7","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Neurology","graph2":"Phase IV","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"11","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"IPN59011","moa":"ACh-alpha-1\/beta-1\/delta\/gamma receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Clementia Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"IPN60130","moa":"ALK-2 receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Sodium Sulfate","moa":"Carbonic anhydrase 2; Carbonic anhydrase 1","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"BN82451B","moa":"COX-1\/COX-2","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Merrimack Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Merrimack Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Merrimack Pharmaceuticals"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Merrimack Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"Irinotecan Hydrochloride","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ipsen","amount2":1.03,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":1.03,"dosageForm":"Infusion","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"IRLAB","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Mesdopetam","moa":"Dopamine D3 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ IRLAB","highestDevelopmentStatusID":"9","companyTruncated":"Ipsen \/ IRLAB"},{"orgOrder":0,"company":"Ipsen","sponsor":"IRLAB","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Mesdopetam","moa":"Dopamine D3 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ IRLAB","highestDevelopmentStatusID":"9","companyTruncated":"Ipsen \/ IRLAB"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"IPN01194","moa":"ERK1\/2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Toremifene Citrate","moa":"Estrogen receptor","graph1":"Undisclosed","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"IPN60090","moa":"Glutaminase-1","graph1":"Oncology","graph2":"Phase I","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"IPN60090","moa":"||Glutaminase-1","graph1":"Oncology","graph2":"Phase I","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Ipsen \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Ipsen","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Triptorelin Pamoate","moa":"Gonadotropin-releasing hormone receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"9","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Triptorelin Pamoate","moa":"Gonadotropin-releasing hormone receptor","graph1":"Oncology","graph2":"Phase IV","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Triptorelin Pamoate","moa":"Gonadotropin-releasing hormone receptor","graph1":"Oncology","graph2":"Phase IV","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Triptorelin Pamoate","moa":"Gonadotropin-releasing hormone receptor","graph1":"Oncology","graph2":"Phase IV","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Triptorelin Pamoate","moa":"Gonadotropin-releasing hormone receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection, Prolonged Release","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Triptorelin Pamoate","moa":"Gonadotropin-releasing hormone receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Triptorelin Pamoate","moa":"Gonadotropin-releasing hormone receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"FRANCE","productType":"Hormone","year":"2017","type":"Inapplicable","leadProduct":"Triptorelin Pamoate","moa":"Gonadotropin-releasing hormone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Triptorelin Pamoate","moa":"Gonadotropin-releasing hormone receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Hormone","year":"2010","type":"Inapplicable","leadProduct":"Triptorelin Pamoate","moa":"Gonadotropin-releasing hormone receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Hormone","year":"2012","type":"Inapplicable","leadProduct":"Triptorelin Pamoate","moa":"Gonadotropin-releasing hormone receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Hormone","year":"2011","type":"Inapplicable","leadProduct":"Somatropin","moa":"Growth hormone receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Diosmectite","moa":"Gut microbiome||Undisclosed","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Sachet","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Diosmectite","moa":"Gut microbiome","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"Histone-lysine N-methyltransferase EZH2","graph1":"Oncology","graph2":"Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"Histone-lysine N-methyltransferase EZH2","graph1":"Oncology","graph2":"Phase I","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"6","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Epizyme","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"Histone-lysine N-methyltransferase EZH2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Epizyme","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Acquisition","leadProduct":"Tazemetostat","moa":"Histone-lysine N-methyltransferase EZH2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Epizyme","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Acquisition","leadProduct":"Tazemetostat","moa":"Histone-lysine N-methyltransferase EZH2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"Histone-lysine N-methyltransferase EZH2","graph1":"Oncology","graph2":"Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ritivixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Elobixibat","moa":"Ileal bile acid transporter","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Albireo Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Albireo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Elobixibat","moa":"Ileal bile acid transporter","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Albireo Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Albireo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Financing","leadProduct":"Elobixibat","moa":"Ileal bile acid transporter","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0.11,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0.11,"dosageForm":"Undisclosed","sponsorNew":"Albireo Pharma \/ Hercules Capital","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Hercules Capital"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Jadeite Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Albireo Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Albireo Pharma"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"FRANCE","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Medison Pharma","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Partnership","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Albireo Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Albireo Pharma"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Albireo Pharma","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Ipsen","amount2":0.94999999999999996,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0.94999999999999996,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Jadeite Medicines","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0.14000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.14000000000000001,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Jadeite Medicines","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Jadeite Medicines"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Divestment","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0.11,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.11,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Jefferies","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Jefferies"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Albireo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Albireo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Albireo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Albireo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Genpharm","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Partnership","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Genpharm","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Genpharm"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Albireo Pharma","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Ipsen","amount2":0.94999999999999996,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0.94999999999999996,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Sagard Healthcare Partners","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Sagard Healthcare Partners","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Sagard Healthcare Partners"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Albireo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Albireo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Tasquinimod","moa":"immunomodulators","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Tasquinimod","moa":"immunomodulators","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Tasquinimod","moa":"immunomodulators","graph1":"Oncology","graph2":"Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Protein","year":"2024","type":"Acquisition","leadProduct":"Mecasermin","moa":"Insulin-like growth factor I receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Eton Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Eton Pharmaceuticals"},{"orgOrder":0,"company":"Ipsen","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Protein","year":"2024","type":"Acquisition","leadProduct":"Mecasermin","moa":"Insulin-like growth factor I receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Eton Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Eton Pharmaceuticals"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Radiolabeled Compound","year":"2018","type":"Inapplicable","leadProduct":"177-Lu 3BP-227","moa":"Neurotensin receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Fusion Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Acquisition","leadProduct":"225-Ac","moa":"||Neurotensin type-1 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Ipsen","amount2":0.57999999999999996,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.57999999999999996,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Fusion Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Ipsen \/ Fusion Pharma"},{"orgOrder":0,"company":"Ipsen","sponsor":"Fusion Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"FPI-2059","moa":"Neurotensin type-1 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"5","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Satoreotide Tetraxetan","moa":"peptides: inhibition of growth hormone release; chelating agents","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Satoreotide Tetraxetan","moa":"peptides: inhibition of growth hormone release; chelating agents","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Satoreotide Trizoxetan","moa":"peptides: inhibition of growth hormone release; chelating agents","graph1":"Oncology","graph2":"Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Satoreotide Trizoxetan","moa":"peptides: inhibition of growth hormone release; chelating agents","graph1":"Oncology","graph2":"Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Satoreotide Trizoxetan","moa":"peptides: inhibition of growth hormone release; chelating agents","graph1":"Oncology","graph2":"Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Elafibranor","moa":"Peroxisome proliferator-activated receptor delta | Peroxisome proliferator-activated receptor alpha","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Elafibranor","moa":"Peroxisome proliferator-activated receptor delta | Peroxisome proliferator-activated receptor alpha","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Elafibranor","moa":"Peroxisome proliferator-activated receptor delta | Peroxisome proliferator-activated receptor alpha","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Elafibranor","moa":"Peroxisome proliferator-activated receptor delta | Peroxisome proliferator-activated receptor alpha","graph1":"Undisclosed","graph2":"Phase I","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Elafibranor","moa":"Peroxisome proliferator-activated receptor delta | Peroxisome proliferator-activated receptor alpha","graph1":"Undisclosed","graph2":"Phase I","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Genfit","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Elafibranor","moa":"Peroxisome proliferator-activated receptor delta | Peroxisome proliferator-activated receptor alpha","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Ipsen","amount2":0.54000000000000004,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0.54000000000000004,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Elafibranor","moa":"Peroxisome proliferator-activated receptor delta | Peroxisome proliferator-activated receptor alpha","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Elafibranor","moa":"Peroxisome proliferator-activated receptor delta | Peroxisome proliferator-activated receptor alpha","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Elafibranor","moa":"Peroxisome proliferator-activated receptor delta | Peroxisome proliferator-activated receptor alpha","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Elafibranor","moa":"Peroxisome proliferator-activated receptor delta | Peroxisome proliferator-activated receptor alpha","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Elafibranor","moa":"Peroxisome proliferator-activated receptor delta | Peroxisome proliferator-activated receptor alpha","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Elafibranor","moa":"Peroxisome proliferator-activated receptor delta | Peroxisome proliferator-activated receptor alpha","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Genfit","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Miscellaneous","year":"2025","type":"Licensing Agreement","leadProduct":"Elafibranor","moa":"||Peroxisome proliferator-activated receptor delta | Peroxisome proliferator-activated receptor alpha","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Ipsen","amount2":0.54000000000000004,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0.54000000000000004,"dosageForm":"Tablet, Film Coated","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Genfit","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Elafibranor","moa":"Peroxisome proliferator-activated receptor delta | Peroxisome proliferator-activated receptor alpha","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Ipsen \/ Genfit","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Genfit"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Elafibranor","moa":"Peroxisome proliferator-activated receptor delta | Peroxisome proliferator-activated receptor alpha","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase IV","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"11","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Calcium Folinate","moa":"Proton-coupled folate transporter; Dihydrofolate reductase","graph1":"Oncology","graph2":"Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"IPN01195","moa":"RAF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Day One Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Tovorafenib","moa":"RAF serine\/threonine protein kinase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0.46000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.46000000000000002,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Palovarotene","moa":"Retinoic acid receptor gamma","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Palovarotene","moa":"Retinoic acid receptor gamma","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Palovarotene","moa":"Retinoic acid receptor gamma","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Palovarotene","moa":"Retinoic acid receptor gamma","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Palovarotene","moa":"Retinoic acid receptor gamma","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Palovarotene","moa":"Retinoic acid receptor gamma","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Palovarotene","moa":"Retinoic acid receptor gamma","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Palovarotene","moa":"Retinoic acid receptor gamma","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Palovarotene","moa":"Retinoic acid receptor gamma","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Palovarotene","moa":"Retinoic acid receptor gamma","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Palovarotene","moa":"Retinoic acid receptor gamma","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Palovarotene","moa":"Retinoic acid receptor gamma","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Palovarotene","moa":"Retinoic acid receptor gamma","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Clementia Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Palovarotene","moa":"Retinoic acid receptor gamma","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"6","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"IPN10200","moa":"SNAP-25","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"IPN10200","moa":"SNAP-25","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"IPN10200","moa":"SNAP-25","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"IPN10200","moa":"SNAP-25","graph1":"Neurology","graph2":"Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Lanreotide Acetate","moa":"Somatostatin receptor 2 | Somatostatin receptor 5","graph1":"Oncology","graph2":"Phase IV","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Lanreotide Acetate","moa":"Somatostatin receptor 2 | Somatostatin receptor 5","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Phillips - Medisize","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2022","type":"Financing","leadProduct":"Lanreotide Acetate","moa":"Somatostatin receptor 2 | Somatostatin receptor 5","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Phillips - Medisize","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Phillips - Medisize"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Lanreotide Acetate","moa":"Somatostatin receptor 2 | Somatostatin receptor 5","graph1":"Oncology","graph2":"Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"BELGIUM","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Lanreotide Acetate","moa":"Somatostatin receptor 5","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Gel","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"9","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Lanreotide Acetate","moa":"Somatostatin receptor 5","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"BELGIUM","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Lanreotide Acetate","moa":"Somatostatin receptor 5","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Lanreotide Acetate","moa":"Somatostatin receptor 5","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Lanreotide Acetate","moa":"Somatostatin receptor 5","graph1":"Undisclosed","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Lanreotide Acetate","moa":"Somatostatin receptor 5","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Lanreotide Acetate","moa":"Somatostatin receptor 5","graph1":"Oncology","graph2":"Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Lanreotide Acetate","moa":"Somatostatin receptor 5","graph1":"Oncology","graph2":"Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Lanreotide Acetate","moa":"Somatostatin receptor 5","graph1":"Endocrinology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Lanreotide Acetate","moa":"Somatostatin receptor 5","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Lanreotide Acetate","moa":"Somatostatin receptor 5","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Lanreotide Acetate","moa":"Somatostatin receptor 5","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Lanreotide Acetate","moa":"Somatostatin receptor 5","graph1":"Endocrinology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Lanreotide Acetate","moa":"Somatostatin receptor 5","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Lanreotide Acetate","moa":"Somatostatin receptor 5","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Lanreotide Acetate","moa":"Somatostatin receptor 5","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Lanreotide Acetate","moa":"Somatostatin receptor 5","graph1":"Oncology","graph2":"Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Lanreotide Acetate","moa":"Somatostatin receptor 5","graph1":"Oncology","graph2":"Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"BIM23B065","moa":"Somatostatin\/Dopamine receptor","graph1":"Endocrinology","graph2":"Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Radiolabeled Compound","year":"2020","type":"Inapplicable","leadProduct":"111-In IPN01087","moa":"SSTR2","graph1":"Oncology","graph2":"Phase I","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"BN83495","moa":"Steryl-sulfatase","graph1":"Oncology","graph2":"Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"BN83495","moa":"Steryl-sulfatase","graph1":"Oncology","graph2":"Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Irosustat","moa":"Steryl-sulfatase","graph1":"Oncology","graph2":"Phase I","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Marengo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Partnership","leadProduct":"Invikafusp Alpha","moa":"T-cell-5-beta receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ipsen","amount2":1.5900000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":1.5900000000000001,"dosageForm":"Infusion","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"7","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2019","type":"Inapplicable","leadProduct":"Fluorouracil","moa":"RNA | DNA | Thymidylate synthase||Thymidylate synthase | RNA | DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"6","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2019","type":"Inapplicable","leadProduct":"Fluorouracil","moa":"RNA | DNA | Thymidylate synthase||Thymidylate synthase | RNA | DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Fluorouracil","moa":"||Thymidylate synthase | RNA | DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2018","type":"Inapplicable","leadProduct":"Fluorouracil","moa":"Thymidylate synthase | RNA | DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"BN80927","moa":"Topoisomerase 1\/Topoisomerase 2","graph1":"Oncology","graph2":"Phase I","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Telotristat Ethyl","moa":"Tryptophan 5-hydroxylase","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"FRANCE","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Telotristat Etiprate","moa":"Tryptophan 5-hydroxylase","graph1":"Nephrology","graph2":"Phase I","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Telotristat Etiprate","moa":"Tryptophan 5-hydroxylase","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"BAKX Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"BKX-001","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Ipsen","amount2":0.84999999999999998,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.84999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"4","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"BLI800","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Biomunex Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"BMX-502","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Ipsen","amount2":0.60999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.60999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"4","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Eziclen","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2013","type":"Inapplicable","leadProduct":"Ferumoxytol","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Ipsen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"FS001","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Ipsen","amount2":1.03,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":1.03,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"4","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Sutro Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"STRO-003","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"4","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Exelixis","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Exelixis"},{"orgOrder":0,"company":"Ipsen","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Cabozantinib","moa":"||Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Exelixis","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Exelixis"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Exelixis","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Exelixis"},{"orgOrder":0,"company":"Ipsen","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Bristol Myers Squibb","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"Cabozantinib","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Exelixis","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Exelixis"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"Cabozantinib","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"ITALY","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"1","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Ipsen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"4","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Exicure","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Ipsen","amount2":1.02,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":1.02,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"2","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"University Of Montreal","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ University Of Montreal","highestDevelopmentStatusID":"2","companyTruncated":"Ipsen \/ University Of Montreal"},{"orgOrder":0,"company":"Ipsen","sponsor":"Exicure","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Undisclosed","year":"2022","type":"Termination","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"Ipsen","amount2":1.02,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","amount2New":1.02,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"2","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Ipsen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"2","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Marengo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Ipsen","amount2":1.2,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":1.2,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"2","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Accent Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Ipsen","amount2":0.45000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.45000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"4","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Skyhawk Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"Ipsen","amount2":1.8,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","amount2New":1.8,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"2","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"IPN60300","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"IPN01203","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ipsen \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals by Ipsen

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : IPN60300 is a Antibody, Unconjugated drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          October 09, 2025

                          Lead Product(s) : IPN60300

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : IPN01203 is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          October 09, 2025

                          Lead Product(s) : IPN01203

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : IPN10200 is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Torticollis.

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          April 22, 2025

                          Lead Product(s) : IPN10200

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Nivolumab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Kidney Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          April 18, 2025

                          Lead Product(s) : Nivolumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase IV

                          Recipient : Gustave Roussy

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Palovarotene is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Liver Failure.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          April 03, 2025

                          Lead Product(s) : Palovarotene

                          Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : IPN01195 is a Other Large Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          February 18, 2025

                          Lead Product(s) : IPN01195

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Tazemetostat is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lymphoma, B-Cell.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          February 13, 2025

                          Lead Product(s) : Tazemetostat

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Recipient : University of Utah

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Through the acquisition, Eton’s bolsters its pediatric endocrinology with the addition of Increlex (mecasermin). It is used to treat pediatric patients 2 years of age and older who suffer from SPIGFD.

                          Product Name : Increlex

                          Product Type : Protein

                          Upfront Cash : Undisclosed

                          December 20, 2024

                          Lead Product(s) : Mecasermin

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved FDF

                          Sponsor : Eton Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          09

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Tazemetostat is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lymphoma.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 18, 2024

                          Lead Product(s) : Tazemetostat

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Recipient : Eric Jacobsen

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Eton will acquire Increlex (mecasermin injection) from Ipsen, which is indicated for treating patients suffering from SPIGFD because their bodies do not make enough IGF-1.

                          Product Name : Increlex

                          Product Type : Protein

                          Upfront Cash : Undisclosed

                          October 03, 2024

                          Lead Product(s) : Mecasermin

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved FDF

                          Sponsor : Eton Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank